Design Therapeutics Net Tangible Assets Over Time
| DSGN Stock | USD 5.97 0.18 2.93% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Design Therapeutics Performance and Design Therapeutics Correlation. Design |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.85) | Revenue Per Share 0.001 | Return On Assets (0.14) | Return On Equity (0.18) |
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Tangible Assets Analysis
Compare Design Therapeutics and related stocks such as Monte Rosa Therapeutics, Werewolf Therapeutics, and Ikena Oncology Net Tangible Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GLUE | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (48.7 M) | 347.5 M | 271.4 M | 312.1 M | 327.7 M |
| HOWL | (24.3 M) | (24.3 M) | (24.3 M) | (24.3 M) | (24.3 M) | (24.3 M) | (24.3 M) | (24.3 M) | (24.3 M) | (24.3 M) | (51.9 M) | 152.8 M | 122.3 M | 140.7 M | 147.7 M |
| IKNA | (45.8 M) | (45.8 M) | (45.8 M) | (45.8 M) | (45.8 M) | (45.8 M) | (45.8 M) | (45.8 M) | (45.8 M) | (61.5 M) | (101 M) | 207.9 M | 147 M | 169 M | 177.5 M |
| STOK | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | 105.1 M | 224.4 M | 286.1 M | 217.8 M | 184.8 M | 212.6 M | 186.4 M |
| ACHL | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 101.3 M | 189.2 M | 289.5 M | 197 M | 226.6 M | 173.7 M |
| ALXO | (51.8 M) | (51.8 M) | (51.8 M) | (51.8 M) | (51.8 M) | (51.8 M) | (51.8 M) | (51.8 M) | (51.8 M) | (70.6 M) | 429.8 M | 363 M | 263.5 M | 303 M | 205.5 M |
| AADI | 58.7 M | 58.7 M | 58.7 M | 58.7 M | 58.7 M | 58.7 M | 58.7 M | 58.7 M | 58.7 M | (9.1 M) | 43.1 M | 132.6 M | 158.4 M | 182.1 M | 191.2 M |
| ADCT | 243.8 M | 243.8 M | 243.8 M | 243.8 M | 243.8 M | 243.8 M | 243.8 M | 243.8 M | 119.6 M | 102.7 M | 325.3 M | 153.1 M | 75.3 M | 67.8 M | 64.4 M |
| ALVR | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (51.5 M) | 353.1 M | 225.3 M | 224.5 M | 258.2 M | 158.6 M |
| ERAS | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (114 M) | 456.5 M | 411.9 M | 473.6 M | 497.3 M |
| CGEM | (1 M) | (1 M) | (1 M) | (1 M) | (1.1 M) | (1.2 M) | (574.9 K) | (20.7 M) | (20.7 M) | (40.8 M) | (77.6 M) | 425 M | 535 M | 615.3 M | 646 M |
| IMCR | 174.7 M | 174.7 M | 174.7 M | 174.7 M | 174.7 M | 174.7 M | 174.7 M | 135 M | 56.3 M | 14.8 M | 55.3 M | 171.5 M | 278.3 M | 320.1 M | 336.1 M |
| CCCC | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (112 M) | 280.8 M | 389.6 M | 289.2 M | 332.6 M | 168.9 M |
Design Therapeutics and related stocks such as Monte Rosa Therapeutics, Werewolf Therapeutics, and Ikena Oncology Net Tangible Assets description
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.My Equities
My Current Equities and Potential Positions
| Design Therapeutics | DSGN |
| Classification | Pharmaceutical Products |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 5.97
Check out Design Therapeutics Performance and Design Therapeutics Correlation. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Design Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.